2025-03-09 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0. Key Figures & Initial Analysis:**

JNJ, Johnson & Johnson, is a multinational healthcare company.  The provided data shows a significant underperformance compared to the S&P 500 (VOO).

**1. Performance Comparison with S&P 500:**

* **JNJ Cumulative Return:** 42.78%
* **VOO Cumulative Return:** 108.62%
* **Return Difference:** -65.8%  (JNJ underperformed VOO by 65.8 percentage points).
* **Relative Divergence:** 28.4% (indicates JNJ's performance is in the lower 28.4 percentile relative to its historical performance against VOO).

The Alpha and Beta analysis across various years reveals inconsistent performance relative to the market (Beta). While positive Alpha values suggest outperformance in some periods, negative Alphas show underperformance.  The substantial variation in CAGR (Compound Annual Growth Rate) and MDD (Maximum Drawdown) indicates significant volatility.  Market capitalization (Cap) generally increased over the period, reflecting JNJ's size and stability.

**2. Recent Price Movement:**

* **Closing Price:** $166.69
* **5-Day Moving Average:** $166.07
* **20-Day Moving Average:** $160.58
* **60-Day Moving Average:** $150.79

The price is above all three moving averages, suggesting a short-term uptrend. The recent price change of $0.52 (0.32%) represents a relatively small, positive daily movement.


**3. Technical Indicators & Expected Return:**

* **RSI:** 76.63 (Approaching overbought territory, suggesting potential short-term correction)
* **PPO:** 0.07 (Positive, indicating upward momentum, but relatively weak)
* **20-Day Relative Divergence Change:** +7.4% (Short-term upward trend)
* **Expected Return (2+ years):** -71.1% (JNJ is expected to underperform the S&P 500 significantly over the long term, based on this projection)


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-10-23 | $1.12   | $22.47B      |
| 2024-07-25 | $1.95   | $22.45B      |
| 2024-05-01 | $1.35   | $21.38B      |
| 2024-02-16 | $1.68   | $21.39B      |
| 2023-10-27 | $10.32  | $21.35B      |

EPS shows significant volatility. The exceptionally high EPS in October 2023 is an outlier and requires further investigation (potential accounting adjustments or one-time gains). Revenue remains relatively stable, but EPS fluctuation is a concern.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |
| 2023-12-31 | $21.39B   | 68.23%        |

Revenue is relatively stable, with high and consistent profit margins.


**Capital and Profitability:**

| Quarter | Equity     | ROE      |
|---------|------------|----------|
| 2024-12-31 | $71.49B   | 4.80%    |
| 2024-09-30 | $70.16B   | 3.84%    |
| 2024-06-30 | $71.54B   | 6.55%    |
| 2024-03-31 | $70.02B   | 4.65%    |
| 2023-12-31 | $68.77B   | 5.89%    |

Equity and ROE fluctuate, but generally remain healthy.


**6. Overall Analysis:**

JNJ shows significant underperformance compared to the S&P 500 over the analyzed period. While the company demonstrates stable revenue and high profit margins, concerns exist regarding the volatility of EPS and the negative long-term expected return relative to the market.  The high RSI suggests potential short-term corrections. The outlier EPS value warrants further investigation.  A deep dive into the reasons for the underperformance and the October 2023 EPS spike is necessary before making any investment decisions.  The projected long-term underperformance (-71.1%) is a serious red flag.  Further due diligence is highly recommended before considering an investment.
